Welcome to our dedicated page for Balchem SEC filings (Ticker: BCPC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Balchem Corporation filings document financial results, governance matters, shareholder votes, and material events for a specialty ingredient manufacturer with Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products segments. Form 8-K reports attach quarterly and annual earnings releases with segment performance, cash flow measures, balance sheet items, debt, and capital-allocation disclosures.
Proxy and shareholder-meeting filings describe board elections, auditor ratification, advisory executive-compensation votes, meeting procedures, corporate governance practices, and executive compensation. Other material-event reports record officer transitions and related governance disclosures, while exhibit and Inline XBRL records support the company’s public reporting framework.
BCPC senior vice president Frederic Boned reported a small tax‑related share withholding tied to equity compensation. On February 8, 2026, 430 shares of common stock were withheld at $173.16 per share to cover taxes on restricted shares granted on February 8, 2023. After this transaction, Boned directly owned 5,215 common shares and indirectly held 441 shares through a 401(k) plan.
Corp SVP Chief Supply Chain Officer Martin Luther Reid reported an administrative share withholding tied to equity compensation. On 02/08/2026, 416 shares of common stock were withheld at $173.16 per share to cover taxes due on the vesting of restricted shares originally granted on 02/08/2023.
After this transaction, Reid beneficially owns 6,975 common shares directly and 542 common shares indirectly through a 401(k) plan. The filing reflects tax settlement related to stock-based compensation rather than an open-market sale.
BCPC executive Carl Martin Bengtsson, EVP & Chief Financial Officer, reported a routine tax-related share withholding. On February 8, 2026, 863 shares of common stock were withheld at $173.16 per share to cover taxes on vesting restricted shares granted on February 8, 2023.
After this transaction, Bengtsson beneficially owned 22,316 common shares directly and 1,086 common shares indirectly through a 401(k) plan. The filing reflects administrative settlement of equity compensation rather than an open-market sale.
Balchem Corporation SVP & Chief HR Officer Michael Brent Tignor reported a routine tax-related share withholding transaction. On 02/08/2026, 373 shares of common stock were withheld at a price of $173.16 per share to cover taxes due upon vesting of restricted shares granted on 02/08/2023.
After this withholding, Tignor beneficially owned 8,750 shares of common stock directly and 1,456 shares indirectly through a 401(k) plan. The filing reflects administrative equity compensation activity rather than an open-market sale.
Balchem (BCPC) officer Martin Luther Reid, SVP Chief Supply Chain Officer, reported an open‑market sale of 1,200 shares of common stock on 11/11/2025 at $154.44 per share. Following the transaction, he beneficially owns 7,391 shares directly and 532 shares indirectly via a 401(k) plan.
Balchem (BCPC) disclosed an insider Form 4 for SVP/GM, Human Nutrition & Health, reporting a Code F transaction on 10/31/2025. The filing shows 1,085 shares of common stock were withheld at $153.39 per share to cover taxes upon vesting of restricted shares granted on 10/31/2022.
Following the transaction, the officer beneficially owns 5,645 shares directly and 415 shares indirectly via a 401(k) plan.
Balchem Corp (BCPC) reported that its SVP and Chief R&D Officer acquired 2,500 shares of common stock on 10/20/2025 via a restricted stock grant at $0 per share. Following the transaction, the reporting person beneficially owns 2,500 shares, held directly.
The award vests ratably over three years—25% on the first anniversary, 25% on the second, and 50% on the third—subject to transfer restrictions under a Restricted Stock Grant Agreement.
Balchem Corp (BCPC) filed a Form 3 for an officer. The reporting person, identified as the company’s SVP and Chief R&D Officer, reported initial beneficial ownership status as of 10/20/2025 and disclosed no securities are beneficially owned.
The filing was made by one reporting person. An Exhibit 24 Power of Attorney is attached, and the form was signed by an attorney-in-fact.
Balchem (BCPC) reported stronger Q3 2025 results. Net sales rose to $267.6 million from $239.9 million, and net earnings increased to $40.3 million from $33.8 million. Diluted EPS was $1.24 versus $1.03. Gross margin expanded as cost of sales rose more slowly than revenue, lifting earnings from operations to $54.6 million from $48.0 million.
Growth was broad-based: Human Nutrition & Health sales were $174.1 million, Animal Nutrition & Health $56.4 million, and Specialty Products $35.7 million. For the nine months, operating cash flow reached $149.3 million, supporting share repurchases and debt reduction. The revolving loan balance declined to $154.0 million from $190.0 million, while cash increased to $65.1 million. Year‑to‑date, the company repurchased 333,594 shares at an average cost of $161.90.
The company noted an EU anti‑dumping investigation into choline chloride imports from China, with proposed definitive duties of 90.0% to 115.9% and final measures expected by the end of 2025. As of October 13, 2025, shares outstanding were 32,386,260.
Balchem Corporation furnished an update on its business by reporting earnings for the quarter ended September 30, 2025. The company issued a press release with the results, which is attached as Exhibit 99.1.
The disclosure was provided under Item 2.02 and is designated as “furnished,” meaning it is not deemed filed under Section 18 of the Exchange Act. Balchem’s common stock trades on Nasdaq under the symbol BCPC.